The Clinical Core will serve two principle missions for the overall SPORE project. First it will provide an active and delineated collaboration with each principle and developmental project aimed at defining experiments that would lead to the design of Phase I and Il clinical studies regardless of the project's timeline to clinical application. Second, it is designed as a comprehensive resource for clinical trials and is specially tailored to therapies for breast cancer emerging from the laboratory and translational programs.. The first goal is to link key personnel in the Clinical Core to individual scientific projects in order to incorporate clinical objectives at all stages of project development. Core members will participate in laboratory meetings pertaining to their assigned project and will lead meetings and planning sessions to formulate clinical development strategies. Members will utilize ongoing collaborations with biotechnology and pharmaceutical industry partners as well as local and national cancer cooperative groups in order to assist individual projects in obtaining IND's and licensure and in the design and implementation of clinical trials. The second goal is accomplished by coordinating a multidisciplinary group of clinicians throughout the Bay Area committed to SPORE-related clinical trials. Current clinical activities and ongoing trials specifically include those that identify patients and set the procedural groundwork for SPORE projects as they approach the clinical trial stage. SPORE-related clinical trials through this Core will be supported by a research database and statistical support through the Epidemiology and Biostatistics Core. Institutional review, data management, and quality assurance will be operational at each clinical site.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058207-08S5
Application #
6664494
Study Section
Project Start
2002-08-01
Project End
2002-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2002
Total Cost
$206,819
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41

Showing the most recent 10 out of 339 publications